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Background: To evaluate the impact of 18F-FDG PET/CT on target volume delineation in gynaecological cancer.
Methods: F-FDG PET/CT based RT treatment planning was performed in 10 patients with locally recurrent (n = 5) or
post-surgical residual gynaecological cancer (n = 5). The gross tumor volume (GTV) was defined by 4 experienced
radiation oncologists first using contrast enhanced CT (GTVCT) and secondly using the fused
18F-FDG PET/CT
datasets (GTVPET/CT). In addition, the GTV was delineated using the signal-to-background (SBR) ratio-based adaptive
thresholding technique (GTVSBR). Overlap analysis were conducted to assess geographic mismatches between the
GTVs delineated using the different techniques. Inter- and intra-observer variability were also assessed.
Results: The mean GTVCT (43.65 cm
3) was larger than the mean GTVPET/CT (33.06 cm
3), p = 0.02. In 6 patients,
GTVPET/CT added substantial tumor extension outside the GTVCT even though 90.4% of the GTVPET/CT was included
in the GTVCT and 30.2% of the GTVCT was found outside the GTVPET/CT. The inter- and intra-observer variability was
not significantly reduced with the inclusion of 18F-FDG PET imaging (p = 0.23 and p = 0.18, respectively). The GTVSBR
was smaller than GTVCT p ≤ 0.005 and GTVPET/CT p≤ 0.005.
Conclusions: The use of 18F-FDG PET/CT images for target volume delineation of recurrent or post-surgical residual
gynaecological cancer alters the GTV in the majority of patients compared to standard CT-definition. The use of
SBR-based auto-delineation showed significantly smaller GTVs. The use of PET/CT based target volume delineation
may improve the accuracy of RT treatment planning in gynaecologic cancer.
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Ultrasound, computed tomography (CT) and magnetic
resonance imaging (MRI) are widely recommended in
the diagnosis of gynaecologic cancer. These conventional
imaging modalities present a high sensitivity, specificity
and accuracy in the primary staging of the disease. How-
ever, the accuracy and specificity of these techniques for
the detection of pelvic tumor recurrences or postsurgical
residual disease remains low owing to limitations in dis-
tinguishing disease from postsurgical changes [1,2]. CT
and MRI may be used for target volume delineation in* Correspondence: hansjorg.vees@hcuge.ch
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reproduction in any medium, provided the orRT treatment planning of gynaecologic carcinomas. How-
ever, a reliable definition of tumor extension is difficult to
assess with either modality, especially after surgery. Re-
cently, 18 fluorodeoxyglucose (18F-FDG) positron emis-
sion tomography – computed tomography (PET/CT) has
been recognized as a valuable tool for the diagnosis of pri-
mary and recurrent gynaecological cancer enabling the
optimization of RT treatment planning [3,4].
The objective of this study is to assess the role of 18F-FDG
PET/CT based target volume delineation in recurrent or
post-surgical residual gynaecologic cancer. We compared
the gross tumor volume (GTV) defined manually by
four experienced radiation oncologists using contrast-
enhanced CT and fused 18F-FDG PET/CT images, as well
as the biological target volumes (BTVs) defined on thed. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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addition, we evaluated the inter- and intra-observer vari-




This prospective study was approved by the institutional
ethical committee. A signed informed consent was
obtained from all patients participating in the study
protocol. Between September 2006 and December 2008,
10 patients with a histologically proven local recurrent
(n = 5) or post-surgical residual (n = 5) gynaecological
cancer were included. Patients didn’t show any evidence
of lymph node or distant metastases. Local recurrences
were observed at a median of 34 months (range, 9-62
months) after surgery in 4 patients and following post-
surgical radio-chemotherapy in 1 patient. The median
age was 64 years (range, 40-81 years). The clinical char-
acteristics and referral patterns of the patient population
are summarized in Table 1.
18F-FDG PET/CT
All 10 patients underwent a diagnostic whole body 18F-
FDG PET/CT scan performed in treatment planning
conditions on the Biograph 16 PET/CT scanner, Siemens









1 Cervix IIIA Primary 36.06
(4.27)
2 Cervix IIB Primary 60.14
(6.60)
3 Cervix IIIB Primary 66.43
(14.16)
4 Uterus IC Primary 2.73
(0.57)
5 Vagina IIIB Primary 21.48
(2.25)
6 Cervix IB Local Recurrence 95.99
(9.81)
7 Vulva IIIB Local Recurrence 16.99
(5.03)
8 Uterus IIIA Local recurrence 6.39
(1.42)
9 Uterus IVA Local Recurrence 26.41
(2.54)
10 Uterus IIIA Local Recurrence 103.84
(1.72)
SBR = Signal-to-background ratio.hours prior to the start of the examination. A forced-
diuresis protocol was used in all patients for a better
differentiation between the tumor and the bladder.
Thirty minutes after the 18F-FDG-injection, each patient
received 0.5 mg of furosemide per kilogram of body
weight (maximum, 40 mg) followed by infusion of
500 mL of physiologic saline through an intravenous
line. One hour after 18F-FDG injection and directly after
voiding of the bladder, patients were placed in scanning
position.
First, a topogram was obtained from the skull to the
upper region of the legs. Secondly, 18F-FDG PET data
were acquired in 3 to 4 minutes bed positions (total of 6
to 7 bed positions) following a low dose CT scan using
for attenuation correction. A diagnostic quality contrast
enhanced CT scan was then performed.
18F-FDG PET, CT and fused 18F-FDG PET/CT images
were displayed for reviewing axial, coronal, and sagittal
planes. All studies were interpreted and reviewed with
knowledge of the patient’s clinical history and results of
previous imaging studies including MRI of the pelvis in
all patients. A combined team of an experienced nuclear
medicine physician and an experienced radiologist inter-
preted the 18F-FDG PET/CT images. A multimodality
computer platform (Syngo Multimodality Workplace,
Siemens Healthcare, Erlangen, Germany) was used for
image review and interpretation. All 18F-FDG PET/CTs (gross tumor volumes)
GTVCT2 GTVPET/CT1 GTVPET/CT2 GTVSBR
Mean (cm3) (SD) Mean (cm3) (SD) Mean (cm3) (SD) (cm3)
36.04 43.28 43.26 25.4
(6.96) (13.20) (10.40)
54.88 34.11 27.67 18.3
(7.03) (5.45) (6.80)
95.06 41.69 48.84 22.0
(10.46) (2.07) (1.94)
4.32 1.91 1.38 1.2
(2.04) (0.43) (0.73)
22.72 12.19 12.33 4.6
(5.03) (2.02) (1.91)
96.05 86.74 70.11 67.8
(19.11) (3.03) (12.86)
15.10 11.23 7.59 5.4
(5.99) (2.67) (0.54)
4.59 3.19 2.24 1.3
(1.54) (0.99) (0.42)
36.45 18.21 15.44 12.7
(6.16) (5.37) (5.93)
106.11 78.06 98.90 54.6
(12.20) (17.14) (2.99)
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uptake were characterized as malignant. Foci of
increased 18F-FDG uptake, with intensity higher than
that of surrounding tissues, in areas unrelated to physio-
logic or benign processes, were defined as malignant.
Tumor uptake of all lesions was assessed quantitatively
using maximum standardized uptake value (SUV)
derived by placing a region of interest encompassing the
tumor on each slice of transaxial plane.
Manual contouring protocol
Four experienced radiation oncologists were asked to
delineate the GTVs on axial slices of the CT (GTVCT)
and the 18F-FDG PET/CT (GTVPET/CT), respectively.
Recent T2-weighted contrast enhanced MRI images
were also available as additional information for con-
touring and for fusion on Syngo multimodality software
(Siemens Healthcare, Erlangen, Germany). All scans
were contoured with knowledge of the additional diag-
nostic images and reports.
The contouring process consists of the following steps:
firstly the radiation oncologists delineated the GTV on
the contrast-enhanced CT images alone (GTVCT1). The
images and reports of the 18F-FDG PET were blinded.
Then, after at least two weeks the observers contoured
the BTV on the fused 18F-FDG PET/CT images
(GTVPET/CT1). To assess the intra-observer variability,
all observers were asked to contour the target volume a
second time two months later on CT images (GTVCT2)
and once again two weeks later on the 18F-FDG PET/CT
images (GTVPET/CT2). They were blinded to their previ-
ous contours as well as to those of the other observers.
The radiation oncologists were all trained in target vol-
ume delineation on PET/CT and were free to adjust the
window, level and contrast setting of the images.
Signal-to-background ratio-based (SBR) adaptive
thresholding (GTVSBR)
For GTVSBR delineation, the maximum signal intensity
of the tumor was defined as the mean activity of the hot-
test voxel and its eight surrounding voxels in a transver-
sal slice, whereas the mean background activity was
obtained from a manually drawn ROI far away from the
tumor [5]. The SBR-thresholding technique has been
described in a previous publication by our group [6].
The GTVSBR were checked visually before approval.
Contour analysis
The delineated contours for both delineation phases
were analyzed separately. Firstly, the volumes contoured
by every observer for GTVCT and GTVPET/CT were cal-
culated for every patient separately and the composite
and common volume of GTVCT and GTVPET/CT were
calculated. The composite volume PET/CT is the sumof GTVCT1 and GTVPET/CT1 while the common volume
PET/CT is the joint volume of GTVCT1 and GTVPET/
CT1 of each observer. To assess the geographic mismatch
between the GTVs delineated using the different seg-
mentation techniques, the following overlap analyses
were performed: (A) The overlap volume of GTVCT1
and GTVPET/CT1, for which overlap was expressed as the
overlap volume of GTVCT1 and GTVPET/CT1 relative to
the CT-based GTVs − overlap fraction (OF) CT1
[OFCT1]; (B) the OF of GTVPET/CT1 and GTVCT1 relative
to the PET/CT-based GTV − overlap fraction PET/CT1
[OFPET/CT1]. In addition, the overlap volume of GTVPET/
CT1 and GTVSBR relative to GTVSBR-OF was also calcu-
lated [OFSBR] (C).
Inter- and intra-observer variability was calculated
using a two-way ANOVA model. Regression analysis
was used to evaluate the difference between calculated
volumes and overlap between GTVs when using the dif-
ferent segmentation tools. Statistical analysis and curve
fitting was performed using PASW Statistics package,
version 18.0 (IBM, Chicago, Illinois, USA). The level of
statistical significance adopted was 0.05.
Results
The contrast enhanced CT scan as well as the 18F-FDG
PET/CT were able to pinpoint the local recurrent or re-
sidual cancer in the pelvis. The median SUVmax of GTVs
was 11.74 (range, 7.55 -17.82). We did not observe any
difference in PET signal between residual tumor and re-
current tumors. Figure 1 presents the mean tumor
volumes using the different manual and SBR delineation
techniques. Error bars indicate standard deviation (SD) on
the mean. Wide variability of the GTVCT and GTVPET/CT
was observed. The mean GTVCT1 (43.65 cm
3, SD 4.84)
was significantly larger than the mean GTVPET/CT1 (33.06
cm3, SD 5.24), p = 0.02. The smallest GTVCT1 and
GTVPET/CT1 was found in patient #6 with 1.89 cm
3 and
0.85 cm3 respectively, and the largest GTVCT in patient
#4 with 120.39cm3, while the largest GTVPET/CT was
observed in patient #10 (101.93 cm3). Figure 2 presents an
example of the GTVs contoured by each observer in each
modality in a patient with a local recurrent cervical can-
cer. The contouring of this case was hampered by the ad-
jacent localization of the bladder and the rectum.
Table 2 summarizes the comparative evaluation of the
CT- and PET/CT-based GTVs. The mean composite vol-
ume was 46.15 cm3 (SD 5.42) and the mean common vol-
ume was 31.48 cm3 (SD 4.21). The mean OFCT1 was 0.63
(SD 0.04). The mean OFPET/CT1 was 0.90 (SD 0.03). In 2
patients, the GTVPET/CT of all observers was included en-
tirely in the GTVCT and in 6 patients, GTVPET/CT added
substantial tumor extension outside the GTVCT.
We found that among four experienced radiation
oncologists, the ratio of largest to smallest GTVs
Figure 1 Comparison of mean tumor volumes using the different manual and SBR delineation techniques. Error bars indicate standard
deviation (SD) on the mean. Results are shown for the gross tumor volume (GTV) delineated on CT (GTVCT1 and GTVCT2) and PET/CT-based GTVs
obtained by manual delineation of contours (GTVPET/CT1 and GTVPET/CT2), and signal-to-background ratio (SBR)-based adaptive thresholding
(GTVSBR).
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median of 1.87 (range, 1.21 to 3.27). When the 18F-FDG-
PET was included, this ratio was reduced to median 1.38
(range, 1.16 to 1.81). The ratio of largest to smallest
GTV was decreased in 9 of 10 patients using PET/CT
for GTV delineation.
Evaluation of inter- and intra-observer variation
The median inter-observer reliability index for the
GTVCT was 0.37 (range, 0.21-0.63) and for the GTVPET/
CT was 0.48 (range, 0.32-0.71); p = 0.23. All physiciansFigure 2 18F-FDG PET with coregistered contrast enhanced CT showe
patient 6 months after total hysterectomy, adnexectomy and pelvic l
defined by four observers on axial, sagittal and coronal contrast enhanced
coronal 18F-FDG PET/CT. In panel B we observed a greater interobserver agcontoured each patient twice and the median intra-
observer percentage of concordance for the GTVCT was
0.49 (range, 0.13-0.89) and for the GTVPET/CT was 0.65
(range, 0.30-0.92) (p = 0.18).
SBR-based auto-contour compared with manual
delineation
The GTVs were delineated both manually and by editing
the SBR-based auto-contour. The results concerning
GTVSBR are shown in Table 1. The mean GTVSBR was
21.33 cm3 (SD 23.87), which is significantly smaller thand a local recurrence with a SUVmax of 16.16 in a 60 year old
ymphadenectomy for an endometrial cancer FIGO IIIA. (A) GTVCTs
CT. (B) GTVPET/CTs defined by four observers on axial, sagittal and
reement and the GTVPET/CTs were smaller than the GTVCTs.
Table 2 Summary of the composite and common volumes of GTVCT1 and GTVPET/CT1 as well as overlap fractions (OFs)
between the GTVCT1, GTVPET/CT1 and GTVSBR
Pat. No. Composite volume PET/CT Common volume PET/CT OFCT1 OFPET/CT1 OFSBR
Mean (cm3) (SD) Mean (cm3) (SD) Mean (cm3) (SD) Mean (cm3) (SD) Mean (cm3) (SD)
1 6.95 5.02 0.72 0.91 0.96
(SD 1.32) (SD 0.95) (SD 0.03) (SD 0.04) (SD 0.04)
2 47.24 46.73 0.55 0.81 1.00
(SD 11.80) (SD 5.43) (SD 0.04) (SD 0.04) (SD 0.00)
3 64.82 44.56 0.59 0.93 1.00
(SD 6.02) (SD 13.68) (SD 0.04) (SD 0.02) (SD 0.00)
4 95.99 99.61 0.57 1.00 1.00
(SD 8.01) (SD 1.63) (SD 0.05) (SD 0.00) (SD 0.00)
5 20.35 20.82 0.45 0.81 0.91
(SD 6.53) (SD 4.45) (SD 0.03) (SD 0.03) (SD 0.08)
6 2.81 2.43 0.77 0.98 1.00
(SD 0.75) (SD 0.62) (SD 0.03) (SD 0.03) (SD 0.00)
7 26.16 12.89 0.61 0.85 0.90
(SD 1.99) (SD 0.94) (SD 0.06) (SD 0.06) (SD 0.05)
8 66.43 50.11 0.46 1.00 1.00
(SD 14.08) (SD 2.31) (SD 0.03) (SD 0.00) (SD 0.00)
9 27.64 19.48 0.67 0.96 1.00
(SD 0.94) (SD 2.78) (SD 0.03) (SD 0.04) (SD 0.00)
10 105.06 97.49 0.87 0.79 0.97
(SD 2.74) (SD 9.30) (SD 0.10) (SD 0.02) (SD 0.03)
The composite volume PET/CT is the sum of GTVCT1 and GTVPET/CT1 while the common volume PET/CT is the joint volume of GTVCT1 and GTVPET/CT1 of each
observer. [OFCT1] is the overlap fraction (OF) of GTVPET/CT1 relative to GTVCT1 while [OFPET/CT1] is the OF of GTVCT1 relative to GTVPET/CT1 and [OFSBR] is the OF of
GTVPET/CT1 relative to GTVSBR. SBR = Signal-to-background ratio.
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GTVPET/CT (p ≤ 0.005). In 6 patients the GTVSBR was
included completely in all GTVCTs and the mean OF be-
tween GTVSBR and GTVPET/CT was 0.97 (SD 0.02).
Comparing the GTVSBR with the GTVPET/CTs, we ob-
serve that in 4 patients the GTVSBR were larger than the
GTVPET/CT.Discussion
CT and MRI have reasonable sensitivity but low specifi-
city in identifying recurrent gynaecologic disease [1,2].
Consequently, significant observer variation has been
noted in contouring the GTVCT [7].
18F-FDG PET/CT
plays an increasingly important role in the staging and
management of gynaecologic cancer including RT treat-
ment planning [3,4]. 18F-FDG PET/CT has demon-
strated a high sensitivity and accuracy of more than 90%
with average specificity in locally advanced or recurrent
gynaecologic pelvic carcinoma. Furthermore 18F-FDG
PET/CT can help to distinguish between tumor recur-
rence and post-therapy changes [4,8]. Kidd et al. have
shown that cervical cancer patients treated with 18F-
FDG PET/CT-guided IMRT had improved survival anddecreased treatment related toxicity compared with
patients treated with non-IMRT radiotherapy [9].
This delineation study evaluated inter- and intra-
observer variability of CT-based and 18F-FDG PET/CT-
based target volume delineation in local recurrent or
postsurgical residual gynaecological cancer. The results
were compared with an automated PET segmented tech-
nique using adaptive thresholding technique. In other
cancer sites such as head and neck and lung, 18F-FDG
PET/CT was reported to decrease inter- and intra-
observer variability in tumor contouring [10]. Our
results suggest that GTV delineation using 18F-FDG
PET/CT could be superior to CT alone in this group of
patients. GTVPET/CT was significantly smaller than the
GTVCT with a trend for reduced inter- and intra-
observer variability using PET/CT. The inter-observer
agreement was moderate for the GTVCT and substantial
for the GTVPET/CT [11]. The inter-observer reliability
was lower than the intra-observer reliability. This is in
agreement with observations made by other authors
[12]. It has been considered that the observers tend to
agree more with themselves rather than with each other.
Inter- and intra-observer variability has been mostly
investigated in lung cancer and the increased observer
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with these findings [10]. Only one study by our group
evaluated the inter-observer variability in PET/CT-based
target volume delineation in the pelvis [13]. A trend of
reduced inter-observer variability has been observed in
the delineation of the intraprostatic recurrence lesion
using 18F-choline PET/CT. In gynaecologic cancer no
inter- or intra-observer variability in PET-based GTV-
delineation has been evaluated until now.
Our study demonstrate that the size of GTVPET/CT
was significantly smaller than the GTVCT with the im-
plementation of a coregistered 18F-FDG PET/CT. When
the GTVSBR volumes were analyzed and compared with
manual delineated target volume, it was observed that
the GTVSBR was significantly smaller than the median
GTVCT and GTVPET/CT. This was also manifested in the
overlap analysis, where the overlap fraction increased
from OFCT1 to OFPET/CT1 and OFSBR. Overall, the com-
parison of GTVs delineated in primary and recurrent
cancer did not result in any significant differences.
The strength of our study includes the use of contrast
enhanced CT scans for GTCT and GTVPET/CT determin-
ation and that the exams were performed on a dedicated
PET/CT scanner for virtual simulation and fused with a
recent MRI. Nevertheless the inter- and intra-observer
variability was relatively high with both imaging modal-
ities, highlighting the difficulty to determine the target
volumes in this group of patients. An automated seg-
mentation of the target volume using the adaptive
thresholding technique could eventually help to reduce
inter- and intra-observer variability. One potential limi-
tation of our study is that the observers were at liberty
to adjust the window, level and contrast setting of the
images. This could have increased the inter- and intra-
observer variability. However, all observers were experi-
enced in PET/CT-based target volume delineation and
were helped by a nuclear medicine physician. Another
drawback of this study is the lack of comparison of the
PET/CT results with pathologic findings after surgery.
The delineation of target volumes and organ at risk is
a very critical step in high-precision RT treatment plan-
ning. Good image quality and reliable delineation proto-
col are important for accurate target volume delineation.
One of the challenges of PET/CT-guided target volume
delineation is the accurate segmentation of noisy and
low resolution functional PET images. This is in particu-
lar true in recurrent or residual gynaecological cancer
where vascular and urinary activity hampers target vol-
ume delineation. The result is a relatively high inter- and
intra-observer variability. Various PET image segmenta-
tion techniques for target volume delineation were
developed and evaluated to overcome this drawback
[11]. Among them, manual contouring by visual examin-
ation is the most commonly used method. Thedetermination of an appropriate window and level for
viewing the PET images is highly operator-dependent
and is subject to high variability between operators [12].
An improved concordance in target volume delinea-
tion using PET/CT implies a greater accuracy and can
help to determine a more appropriate treatment plan. In
our study, the inter-observer variability coefficient pre-
vailed is still relatively high. Variability negatively
impacts the quality of treatments delivered to cancer
patients. Alternatively an automated segmented target
volume could be considered. There is consensus in the
need for highly objective and automatic segmentation
methods, and various groups have observed that semi-
or fully-automated delineation techniques reduce inter-
observer variability and improve reproducibility [10].
The adaptive thresholding technique is one of the most
widely used segmentation techniques for target volume
determination in clinical setting. However, knowledge of
the true target volume in relation the GTVSBR in gynae-
cologic tumors is needed for validation purposes. PET-
based target volume delineation in gynaecologic tumors
is actually not recommended outside clinical studies. It
has to be emphasized that both patients with recurrent
or postsurgical residual gynaecologic cancer are challen-
ging cohorts for reliable target volume delineation and
thus it is more likely that high inter- and intra-observer
variability will result. In the absence of a more accurate
information on the target volume position in gynaecolo-
gic cancer, a composite of GTVCT and GTVPET/CT can
be recommended to optimize the GTV definition.Conclusions
This delineation study showed that GTVPET/CT was sig-
nificantly smaller than GTVCT. The reduction was larger
when the adaptive thresholding-based semi-automated
contouring algorithm was used. GTVPET/CT added sub-
stantial tumor extension outside the GTVCT in 60% of
the patients. The combination of a matched 18F-FDG
PET/CT reduced the inter- and intra-observer variation
in the delineation of gynaecological cancer however
the difference was not significant. Target volume
delineation may be improved with the inclusion of 18F-
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